{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:51:12Z","timestamp":1793407872078,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019844","name":"AlphaTau Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019844","id-type":"DOI","asserted-by":"publisher"}]},{"name":"HekaBio K.K."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of diffusing alpha-emitter radiation therapy (DaRT) for recurrent head and neck cancer (rHNC) after radiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was a multicenter prospective clinical trial. Eligibility criteria included all patients with biopsy-proven rHNC and history of radiotherapy. The efficacy of DaRT was evaluated in terms of tumor shrinkage after 10\u00a0weeks of DaRT seed implantation. To assess safety of DaRT, radioactivity levels in blood and urine were measured, and incidence and grade of adverse events (AEs) were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between 2019 and 2021, DaRT was performed in 11 patients and completed in 10 patients with 11 tumors. The tumor sites included the tongue (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093), buccal mucosa (2), lips (2), floor of the mouth (1), soft palate (1), nose (1), and subcutaneous layer (1). Nine tumors were confirmed to be squamous cell carcinoma, and the remaining two tumors were basal cell carcinoma and neuroblastoma. Complete response (CR) and partial response (PR) were observed in three and six patients, respectively. The response rate was 81.8%. The maximum average radioactivity levels in blood and urine were 42.5\u00a0Bq\/cm\n                      <jats:sup>3<\/jats:sup>\n                      and 8.4\u00a0Bq\/cm\n                      <jats:sup>3<\/jats:sup>\n                      , respectively, on the second day after implantation. Forty AEs were observed in all 11 patients, including 22 Grade 1 AEs, 16 Grade 2, and 2 Grade 3 (hypertension and seed remnants).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The initial response of rHNC after radiotherapy to DaRT was favorable, and the incidence and grade of AEs were acceptable, as compared to existing therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-025-02720-6","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:15:27Z","timestamp":1739924127000},"page":"893-903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of diffusing alpha-emitter radiation therapy (DaRT) for head and neck cancer recurrence after radiotherapy"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9435-1503","authenticated-orcid":false,"given":"Ryo-ichi","family":"Yoshimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Notake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Igaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Umezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Kadoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Jingu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Itami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"2720_CR1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/hed.26485","volume":"43","author":"M Svajdova","year":"2021","unstructured":"Svajdova M, Dubinsky P, Kazda T (2021) Radical external beam re-irradiation in the treatment of recurrent head and neck cancer: critical review. Head Neck 43:354\u2013366","journal-title":"Head Neck"},{"key":"2720_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1177\/0194599818818443","volume":"160","author":"JBW Elbers","year":"2019","unstructured":"Elbers JBW, Al-Mamgani A, van den Brekel MWM et al (2019) Salvage surgery for recurrence after radiotherapy for squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg 160:1023\u20131033","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2720_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.oraloncology.2019.08.017","volume":"98","author":"F Dionisi","year":"2019","unstructured":"Dionisi F, Fiorica F, D\u2019Angelo E et al (2019) Organs at risk\u2019s tolerance and dose limits for head and neck cancer reiiradiation: a literature review. Oral Oncol 98:35\u201347","journal-title":"Oral Oncol"},{"key":"2720_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s12032-018-1096-5","volume":"35","author":"A Guidi","year":"2018","unstructured":"Guidi A, Codeca C, Ferrari D (2018) Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review. Med Oncol 35:37","journal-title":"Med Oncol"},{"key":"2720_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/bjc.1990.59","volume":"61","author":"The Liverpool Head and Neck Oncology Group","year":"1990","unstructured":"The Liverpool Head and Neck Oncology Group (1990) A phase III randomized trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Br J Cancer 61:311\u2013315","journal-title":"Br J Cancer"},{"key":"2720_CR6","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116\u20131127","journal-title":"N Engl J Med"},{"issue":"7","key":"2720_CR7","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","volume":"17","author":"TY Seiwert","year":"2016","unstructured":"Seiwert TY, Burtness B, Mehra R et al (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17(7):956\u2013965","journal-title":"Lancet Oncol"},{"issue":"32","key":"2720_CR8","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","volume":"34","author":"LQ Chow","year":"2016","unstructured":"Chow LQ, Haddad R, Gupta S et al (2016) Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 34(32):3838\u20133845","journal-title":"J Clin Oncol"},{"issue":"19","key":"2720_CR9","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G, Fayette JJ et al (2016) Nivolumab for recurrent squamous cell carcinoma of the head and neck. N Engl J Med 375(19):1856\u20131867","journal-title":"N Engl J Med"},{"key":"2720_CR10","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1088\/0031-9155\/52\/16\/021","volume":"52","author":"L Arazi","year":"2007","unstructured":"Arazi L, Cooks T, Schmidt M et al (2007) Treatment of solid tumors by interstitial release of recoiling short-lived alpha emitters. Phys Med Biol 52:5025\u20135042","journal-title":"Phys Med Biol"},{"key":"2720_CR11","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/ijc.23268","volume":"122","author":"T Cooks","year":"2008","unstructured":"Cooks T, Arazi L, Schmidt M et al (2008) Growth retardation and destruction of experimental squamous cell carcinoma by interstitial radioactive wires releasing diffusing alpha-emitting atoms. Int J Cancer 122:1657\u20131664","journal-title":"Int J Cancer"},{"key":"2720_CR12","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1088\/0031-9155\/55\/4\/020","volume":"55","author":"L Arazi","year":"2010","unstructured":"Arazi L, Cooks T, Schmidt M et al (2010) The treatment of solid tumors by alpha emitters released from (224) Ra-loaded sources-internal dosimetry analysis. Phys Med Biol 55:1203\u20131218","journal-title":"Phys Med Biol"},{"key":"2720_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.trsl.2011.08.009","volume":"159","author":"G Horev-Drori","year":"2012","unstructured":"Horev-Drori G, Cooks T, Bittan H et al (2012) Local control of experimental malignant pancreatic tumors by treatment with a combination of chemotherapy and intratumoral (224) Radium-loaded wires releasing alpha-emitting atoms. Transl Res 159:32\u201341","journal-title":"Transl Res"},{"key":"2720_CR14","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00262-016-1878-6","volume":"65","author":"H Confino","year":"2016","unstructured":"Confino H, Schmidt M, Efrati M et al (2016) Inhibition of mouse breast adenocarcinoma growth by ablation with intratumoral alpha-irradiation combined with inhibitors of immunosuppression and CpG. Cancer Immunol Immunother 65:1149","journal-title":"Cancer Immunol Immunother"},{"key":"2720_CR15","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijrobp.2019.10.048","volume":"106","author":"A Popovtzer","year":"2020","unstructured":"Popovtzer A, Rosenfeld E, Mizrachi A et al (2020) Initial safety and tumor control results from a first-in-human multicenter prospective trial evaluating a novel alpha-emitting radionuclide for the treatment squamous cell carcinomas of the skin and head and neck. Int J Radiat Oncol Biol Phys 106:571\u2013578","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2720_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.12824","volume":"6","author":"MA D\u2019Andrea","year":"2023","unstructured":"D\u2019Andrea MA, VanderWalde NA, Ballo MT et al (2023) Feasibility and safety of diffusing alpha-emitter radiation therapy for recurrent or unresectable skin cancers. JAMA Netw Open 6(5):e2312824","journal-title":"JAMA Netw Open"},{"key":"2720_CR17","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.3390\/cancers16132312","volume":"16","author":"A Popovtzer","year":"2024","unstructured":"Popovtzer A, Mizrachi A, D\u2019Andrea MA et al (2024) Extended follow-up outcomes from pooled prospective studies evaluating efficacy of interstitial alpha radionuclide treatment for skin and head and neck cancers. Cancers 16:2312","journal-title":"Cancers"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02720-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02720-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02720-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T02:04:18Z","timestamp":1745287458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02720-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2720"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02720-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5335358\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"25 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ryo-ichi Yoshimura served as an advisory role to HekaBio K.K.; Kazuma Toda received a research funding from HekaBio K.K.; Masahiko Miura served as an advisory role to HekaBio K.K.; Naoya Murakami received honoraria from Elekta K.K., Chiyoda Technol, Teleflex, and Bayer Japan, and a research funding from Elekta K.K.; Keiichi Jingu received honoraria from Novartis pharma K.K. and a research funding from Elekta K.K.; Jun Itami received honoraria from HekaBio K.K. and a research funding from Teleflex; Hiroshi Watanabe, Ryoichi Notake, Hiroshi Igaki, Satoshi Nakamura, Rei Umezawa, and Noriyuki Kadoya have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}